GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenetp Inc (OTCPK:RGTPQ) » Definitions » Net Cash per Share

Regenetp (Regenetp) Net Cash per Share : $0.10 (As of Mar. 2023)


View and export this data going back to 1999. Start your Free Trial

What is Regenetp Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Regenetp's Net Cash per Share for the quarter that ended in Mar. 2023 was $0.10.

The historical rank and industry rank for Regenetp's Net Cash per Share or its related term are showing as below:

RGTPQ's Price-to-Net-Cash is not ranked *
in the Biotechnology industry.
Industry Median: 4.16
* Ranked among companies with meaningful Price-to-Net-Cash only.

Regenetp Net Cash per Share Historical Data

The historical data trend for Regenetp's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenetp Net Cash per Share Chart

Regenetp Annual Data
Trend Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Dec19 Dec20 Dec21 Dec22
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 75.59 13.29 3.35 2.26 0.72

Regenetp Quarterly Data
Apr18 Jul18 Oct18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.63 2.52 1.51 0.72 0.10

Competitive Comparison of Regenetp's Net Cash per Share

For the Biotechnology subindustry, Regenetp's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenetp's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenetp's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Regenetp's Price-to-Net-Cash falls into.



Regenetp Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Regenetp's Net Cash per Share for the fiscal year that ended in Dec. 2022 is calculated as

Net Cash per Share (A: Dec. 2022 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(11.446-6.229-0)/7.25819
=0.72

Regenetp's Net Cash per Share for the quarter that ended in Mar. 2023 is calculated as

Net Cash per Share (Q: Mar. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(6.394-5.628-0)/7.32501
=0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regenetp  (OTCPK:RGTPQ) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Regenetp Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Regenetp's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Regenetp (Regenetp) Business Description

Traded in Other Exchanges
N/A
Address
1960 South 4250 West, Salt Lake City, UT, USA, 84104
Regenetp Inc Formerly PolarityTE Inc is a clinical-stage biotechnology company developing regenerative tissue products and biomaterials. It's focused on transforming the lives of patients by discovering, designing, and developing regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences. Its product includes SkinTE used for repair, reconstruction, replacement, or regeneration of the skin in patients who have or require treatment of acute and chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. It operates in two segments: the regenerative medicine business segment and the contract research segment.
Executives
Peter A Cohen director 40 WEST 57TH STREET, SUITE 2020, NEW YORK NY 10019
David B Seaburg director 1960 S 4250 W, SALT LAKE CITY UT 84104
Richard Hague officer: Chief Operating Officer 1960 S 4250 W, SALT LAKE CITY UT 84104
Cameron J. Hoyler other: General Counsel 1960 S 4250 W, SALT LAKE CITY UT 84104
Jeffrey Hansen Dyer director 4041-T HADLEY ROAD, SOUTH PLAINFIELD NJ 07080
Jessica Xiaolin Shen director POLARITYTE, INC. (NASDAQ: PTE), 1960 S. 4250 WEST, SALT LAKE CITY UT 84104
Chris Nolet director C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Paul Elliot Mann officer: Chief Financial Officer C/O ASP ISOTOPES INC., 433 PLAZA REAL, SUITE 275, BOCA RATON FL 33432
Jacob Alexander Patterson officer: Chief Financial Officer 14822 S. ROSESCAPE CIRCLE, HERRIMAN UT 84096
Denver Lough 10 percent owner, other: Prior D&O within 90 days 4041-T HADLEY ROAD, SOUTH PLAINFIELD NJ 07080
Rainer M Erdtmann director 1073 ARLINGTON BLVD., EL CERRITO CA 94530
Edward Winslow Swanson director, officer: Chief Operating Officer 181 DANTE AVE., TUCKAHOE NY 07070
Steve Gorlin director 150 GULF SHORE DRIVE, UNIT 601, DESTIN FL 32541
Minnie Baylor-henry director C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803
Willie C Bogan director 1943, ROSECREST DRIVE, OAKLAND CA 94602